ABVC BioPharma (ABVC) Q4 2025 earnings summary

Executive summary

• No revenue recognized in 2025 due to lack of payments from licensees; 2024 revenue was $509,589, mainly from licensing and CDMO services.

• Net loss increased to $8.4M in 2025 from $5.3M in 2024, driven by higher operating expenses and stock-based compensation.

• Working capital deficit of $3.7M as of December 31, 2025; cash and cash equivalents at $681K.

• Substantial doubt raised about ability to continue as a going concern due to recurring losses and negative cash flows.

Financial highlights

• Operating expenses rose 37% year-over-year to $7.2M, mainly due to increased stock-based compensation.

• Interest expense decreased 66% to $249K in 2025 due to lower convertible note balances.

• Cash used in operating activities was $3.0M in 2025, up from $1.8M in 2024.

• Cash provided by financing activities was $4.6M in 2025, mainly from private placements and warrant exercises.

• No dividends paid; company does not anticipate paying dividends in the foreseeable future.

Outlook and guidance

• Management plans to improve operations, generate positive cash flows, and raise additional capital through offerings or related party support.

• Company continues to focus on advancing clinical trials and out-licensing drug candidates post-Phase II.